Cascinu S, Fedeli A, Fedeli S L, Catalano G
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy.
Eur J Cancer. 1992;28(2-3):482-3. doi: 10.1016/s0959-8049(05)80082-6.
Chemotherapy treatment with combination of 5-fluorouracil and leucovorin or interferon alpha determined an incidence of severe diarrhoea of 10 and 20%, respectively. Up to date no treatment for this condition has been defined. 21 patients affected by advanced colorectal cancer and 6 patients affected by advanced pancreatic cancer received octreotide as treatment for severe diarrhoea following chemotherapy with 5-fluorouracil/leucovorin (Machover's regimen) or 5-fluorouracil/interferon (Wadler's regimen) combination. Octreotide was administered by subcutaneous injection of 50 micrograms twice daily on the first day and 100 micrograms twice daily on the second and third day. 26 patients had total cessation of diarrhoea: 4 patients within the first day, 6 within the second day and 16 within the third day. 1 patient had no change and after the last administration of octreotide he was treated with loperamide and intravenous hydration. Side effects have been mild. In summary octreotide seems to be an effective agent in the management of chemotherapy related diarrhoea.
5-氟尿嘧啶与亚叶酸或干扰素α联合进行化疗时，严重腹泻的发生率分别为10%和20%。迄今为止，尚未确定针对这种情况的治疗方法。21例晚期结直肠癌患者和6例晚期胰腺癌患者接受了奥曲肽治疗，以缓解5-氟尿嘧啶/亚叶酸（马乔弗方案）或5-氟尿嘧啶/干扰素（瓦德勒方案）联合化疗后的严重腹泻。奥曲肽通过皮下注射给药，第一天每日两次，每次50微克，第二天和第三天每日两次，每次100微克。26例患者腹泻完全停止：4例在第一天内，6例在第二天内，16例在第三天内。1例患者病情无变化，在最后一次注射奥曲肽后，他接受了洛哌丁胺和静脉补液治疗。副作用较轻。总之，奥曲肽似乎是治疗化疗相关性腹泻的有效药物。
